
Advancing Second-Line Therapy in ÂExtensive-Stage Small-Cell Lung Cancer
Small-cell lung cancer (SCLC) remains one of the most aggressive malignancies, characterized by high relapse rates and a dismal prognosis, particularly in the second-line setting, where standard therapies…
Durvalumab bei Patienten mit PD-L1-positivem, fort- geschrittenem NSCLC und reduziertem Allgemeinzustand
Akute myeloische Leukämie im Kindes- und Jugendalter
